Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RDGL .0091 SHARES GETTING SOAKED UP. $0.10 52 week high will be broken. whales.. RDGL will break its 10 cent 52 week high. TOO MANY WHALES IN THE WATER NOW. LIQUIDDDDD TINY FLOAT.
isopet results show effective in killing cancer in cats. ONLY 81 MILLION O\S. Thin to multipennies. Will not be down here for long.
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL THANKS FOR THE CHEAPIES!! WEEEEEEEEEEEEEE! Like stealing candy from a baby. Too easy. Not much more to say read the stickies. STUDY THE PRODUCT. See you at 10 cents plus. Guys set your sells above 10th cents limit shares available to short. Short cover FRIDAY!! Veteran traders know what ingredients this holds to go viral and PARABOLIC. Too easy. You see those shares getting SWALLOWED??
$RDGL .011 5 REASONS A 2000% RUN INEVITABLE, this #biotech has limitless POTENTIAL I would not be surprised to see it break $5 sometime in its future and I'm being very honest. An investor recently purchased over 5 million shares! Do your due diligence, the more you read the more you will understand. BIG MONEY traders LOADING HEAVY. VOLUME has gone up over 20x. Don't sleep.
I ALERTED IT AT 003 LAST WEEK IT RAN OVER 500% IN DAYS. NOW TOP 5 MOST READ AND MOST POSTED ON IHUB. GOING VIRAL
https://www.slideshare.net/mobile/RedChip/advanced-medical-isotope-corp-presentation-83345101?ref=https://www.redchip.com/company/Biotech/RDGL/376/RDGL
$RDGL TOP 5 MUST READS! All from Page 1 of the FORM S-1 filing with the Securities and Exchange Commission on February 8 , 2018, link included right below this.....
https://backend.otcmarkets.com/otcapi/company/sec-filings/12530010/content/html
1) Radiogel approved to treat feline sarcomas and canine soft tissue sarcomas, which is the most common type of cancer in animals"
2) Battelle has granted us an exclusive license to patents covering the manufacturing, processing and applications of RadioGel™ (the “ Battelle License ”). Other intellectual property protection for RadioGel™ includes proprietary production processes and trademark protection in 17 countries. We plan to continue efforts to develop new refinements on the production process, and the product and application hardware, as a basis for future patents."
3) A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting early in 2019. The safety review at UC Davis is almost completed. They will be treating prostate and liver cancer in dogs in 2019."
4) These animal therapies will focus on creating labels that describe the procedures in detail as a guide to future veterinarians. The labels will be voluntarily submitted to the FDA for review. They will then be used as data for future FDA applications in the medical sector and as key intellectual property for licensing to private veterinary clinics.
5)We anticipate that future profit will be derived from direct sales of RadioGel™ and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally.
Business Summary
Heres the full Page 1 excerpts: As filed with the Securities and Exchange Commission on February 8 , 2018
https://backend.otcmarkets.com/otcapi/company/sec-filings/12530010/content/html
"Our IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospitals to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. In January 2018, we received notification from the FDA that the Center for Veterinary Medicine Product Classification Group ruled that RadioGel™ is classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas, which is the most common type of cancer in animals. In addition, the FDA also reviewed and approved our label, which is a requirement for any device used in animals.
"RadioGel™ incorporates patented technology developed for Battelle Memorial Institute (“ Battelle ”) at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers. Battelle has granted us an exclusive license to patents covering the manufacturing, processing and applications of RadioGel™ (the “ Battelle License ”). Other intellectual property protection for RadioGel™ includes proprietary production processes and trademark protection in 17 countries. We plan to continue efforts to develop new refinements on the production process, and the product and application hardware, as a basis for future patents."
"We have worked with four different university veterinarian hospitals on RadioGel™ testing and therapy. Colorado State University demonstrated the procedures and the CT and PET-CT imaging of RadioGel. Washington State University treated four cats for feline sarcoma. They concluded that the product was safe and effective in killing cancer cells. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting early in 2019. The safety review at UC Davis is almost completed. They will be treating prostate and liver cancer in dogs in 2019."
These animal therapies will focus on creating labels that describe the procedures in detail as a guide to future veterinarians. The labels will be voluntarily submitted to the FDA for review. They will then be used as data for future FDA applications in the medical sector and as key intellectual property for licensing to private veterinary clinics.
We anticipate that future profit will be derived from direct sales of RadioGel™ and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally.
Please do not take any information I post here as investment advice on whether to buy, hold or sell a stock or any security. Please always do your own research. It is your responsibility alone on how to invest your own money
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
$RDGL .011 5 REASONS A 2000% RUN INEVITABLE, this #biotech has limitless POTENTIAL I would not be surprised to see it break $5 sometime in its future and I'm being very honest. An investor recently purchased over 5 million shares! Do your due diligence, the more you read the more you will understand. BIG MONEY traders LOADING HEAVY. VOLUME has gone up over 20x. Don't sleep.
I ALERTED IT AT 003 LAST WEEK IT RAN OVER 500% IN DAYS. NOW TOP 5 MOST READ AND MOST POSTED ON IHUB. GOING VIRAL
https://www.slideshare.net/mobile/RedChip/advanced-medical-isotope-corp-presentation-83345101?ref=https://www.redchip.com/company/Biotech/RDGL/376/RDGL
$RDGL TOP 5 MUST READS! All from Page 1 of the FORM S-1 filing with the Securities and Exchange Commission on February 8 , 2018, link included right below this.....
https://backend.otcmarkets.com/otcapi/company/sec-filings/12530010/content/html
1) Radiogel approved to treat feline sarcomas and canine soft tissue sarcomas, which is the most common type of cancer in animals"
2) Battelle has granted us an exclusive license to patents covering the manufacturing, processing and applications of RadioGel™ (the “ Battelle License ”). Other intellectual property protection for RadioGel™ includes proprietary production processes and trademark protection in 17 countries. We plan to continue efforts to develop new refinements on the production process, and the product and application hardware, as a basis for future patents."
3) A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting early in 2019. The safety review at UC Davis is almost completed. They will be treating prostate and liver cancer in dogs in 2019."
4) These animal therapies will focus on creating labels that describe the procedures in detail as a guide to future veterinarians. The labels will be voluntarily submitted to the FDA for review. They will then be used as data for future FDA applications in the medical sector and as key intellectual property for licensing to private veterinary clinics.
5)We anticipate that future profit will be derived from direct sales of RadioGel™ and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally.
Business Summary
Heres the full Page 1 excerpts: As filed with the Securities and Exchange Commission on February 8 , 2018
https://backend.otcmarkets.com/otcapi/company/sec-filings/12530010/content/html
"Our IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospitals to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. In January 2018, we received notification from the FDA that the Center for Veterinary Medicine Product Classification Group ruled that RadioGel™ is classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas, which is the most common type of cancer in animals. In addition, the FDA also reviewed and approved our label, which is a requirement for any device used in animals.
"RadioGel™ incorporates patented technology developed for Battelle Memorial Institute (“ Battelle ”) at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers. Battelle has granted us an exclusive license to patents covering the manufacturing, processing and applications of RadioGel™ (the “ Battelle License ”). Other intellectual property protection for RadioGel™ includes proprietary production processes and trademark protection in 17 countries. We plan to continue efforts to develop new refinements on the production process, and the product and application hardware, as a basis for future patents."
"We have worked with four different university veterinarian hospitals on RadioGel™ testing and therapy. Colorado State University demonstrated the procedures and the CT and PET-CT imaging of RadioGel. Washington State University treated four cats for feline sarcoma. They concluded that the product was safe and effective in killing cancer cells. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting early in 2019. The safety review at UC Davis is almost completed. They will be treating prostate and liver cancer in dogs in 2019."
These animal therapies will focus on creating labels that describe the procedures in detail as a guide to future veterinarians. The labels will be voluntarily submitted to the FDA for review. They will then be used as data for future FDA applications in the medical sector and as key intellectual property for licensing to private veterinary clinics.
We anticipate that future profit will be derived from direct sales of RadioGel™ and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally.
Please do not take any information I post here as investment advice on whether to buy, hold or sell a stock or any security. Please always do your own research. It is your responsibility alone on how to invest your own money
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
$RDGL .011 5 REASONS A 2000% RUN INEVITABLE, this #biotech has limitless POTENTIAL I would not be surprised to see it break $5 sometime in its future and I'm being very honest. An investor recently purchased over 5 million shares! Do your due diligence, the more you read the more you will understand. BIG MONEY traders LOADING HEAVY. VOLUME has gone up over 20x. Don't sleep.
I ALERTED IT AT 003 LAST WEEK IT RAN OVER 500% IN DAYS. NOW TOP 5 MOST READ AND MOST POSTED ON IHUB. GOING VIRAL
https://www.slideshare.net/mobile/RedChip/advanced-medical-isotope-corp-presentation-83345101?ref=https://www.redchip.com/company/Biotech/RDGL/376/RDGL
$RDGL TOP 5 MUST READS! All from Page 1 of the FORM S-1 filing with the Securities and Exchange Commission on February 8 , 2018, link included right below this.....
https://backend.otcmarkets.com/otcapi/company/sec-filings/12530010/content/html
1) Radiogel approved to treat feline sarcomas and canine soft tissue sarcomas, which is the most common type of cancer in animals"
2) Battelle has granted us an exclusive license to patents covering the manufacturing, processing and applications of RadioGel™ (the “ Battelle License ”). Other intellectual property protection for RadioGel™ includes proprietary production processes and trademark protection in 17 countries. We plan to continue efforts to develop new refinements on the production process, and the product and application hardware, as a basis for future patents."
3) A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting early in 2019. The safety review at UC Davis is almost completed. They will be treating prostate and liver cancer in dogs in 2019."
4) These animal therapies will focus on creating labels that describe the procedures in detail as a guide to future veterinarians. The labels will be voluntarily submitted to the FDA for review. They will then be used as data for future FDA applications in the medical sector and as key intellectual property for licensing to private veterinary clinics.
5)We anticipate that future profit will be derived from direct sales of RadioGel™ and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally.
Business Summary
Heres the full Page 1 excerpts: As filed with the Securities and Exchange Commission on February 8 , 2018
https://backend.otcmarkets.com/otcapi/company/sec-filings/12530010/content/html
"Our IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospitals to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. In January 2018, we received notification from the FDA that the Center for Veterinary Medicine Product Classification Group ruled that RadioGel™ is classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas, which is the most common type of cancer in animals. In addition, the FDA also reviewed and approved our label, which is a requirement for any device used in animals.
"RadioGel™ incorporates patented technology developed for Battelle Memorial Institute (“ Battelle ”) at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers. Battelle has granted us an exclusive license to patents covering the manufacturing, processing and applications of RadioGel™ (the “ Battelle License ”). Other intellectual property protection for RadioGel™ includes proprietary production processes and trademark protection in 17 countries. We plan to continue efforts to develop new refinements on the production process, and the product and application hardware, as a basis for future patents."
"We have worked with four different university veterinarian hospitals on RadioGel™ testing and therapy. Colorado State University demonstrated the procedures and the CT and PET-CT imaging of RadioGel. Washington State University treated four cats for feline sarcoma. They concluded that the product was safe and effective in killing cancer cells. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting early in 2019. The safety review at UC Davis is almost completed. They will be treating prostate and liver cancer in dogs in 2019."
These animal therapies will focus on creating labels that describe the procedures in detail as a guide to future veterinarians. The labels will be voluntarily submitted to the FDA for review. They will then be used as data for future FDA applications in the medical sector and as key intellectual property for licensing to private veterinary clinics.
We anticipate that future profit will be derived from direct sales of RadioGel™ and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally.
Please do not take any information I post here as investment advice on whether to buy, hold or sell a stock or any security. Please always do your own research. It is your responsibility alone on how to invest your own money
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
$RDGL 42 MILLION VOLUME!!! $0.10 52 week high will be broken. whales. 38 million VOLUME? MONEY. Did you see those MASSIVE BULK SMACKS on the ask?. 670k MONSTER ASK SMACK AND MULTIPLE ASK SMACKS of 200k and above. RDGL will break its 10 cent 52 week high. TOO MANY WHALES IN THE WATER NOW. LIQUIDDDDD TINY FLOAT.
isopet results show effective in killing cancer in cats. ONLY 81 MILLION O\S. Thin to multipennies. Will not be down here for long.
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
$RDGL 42 MILLION VOLUME!!! $0.10 52 week high will be broken. whales. 38 million VOLUME? MONEY. Did you see those MASSIVE BULK SMACKS on the ask?. 670k MONSTER ASK SMACK AND MULTIPLE ASK SMACKS of 200k and above. RDGL will break its 10 cent 52 week high. TOO MANY WHALES IN THE WATER NOW. LIQUIDDDDD TINY FLOAT.
isopet results show effective in killing cancer in cats. ONLY 81 MILLION O\S. Thin to multipennies. Will not be down here for long.
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
$RDGL OMG DID U SEE 5 MILLION SHARES SWALLOWED by whales? 52WKHIGH 10 cents 38 million VOLUME? MONEY. Did you see those MASSIVE BULK SMACKS on the ask?. 670k buy just went through 40 minutes ago. Massive hits. RDGL will break its 10 cent 52 week high. TOO MANY WHALES IN THE WATER NOW. LIQUIDDDDD TINY FLOAT.
isopet results show effective in killing cancer in cats. ONLY 81 MILLION O\S. Thin to multipennies. Will not be down here for long.
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
$RDGL OMG DID U SEE 5 MILLION SHARES SWALLOWED by whales? 52WKHIGH 10 cents 38 million VOLUME? MONEY. Did you see those MASSIVE BULK SMACKS on the ask?. 670k buy just went through 40 minutes ago. Massive hits. RDGL will break its 10 cent 52 week high. TOO MANY WHALES IN THE WATER NOW. LIQUIDDDDD TINY FLOAT.
isopet results show effective in killing cancer in cats. ONLY 81 MILLION O\S. Thin to multipennies. Will not be down here for long.
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
$RDGL OMG DID U SEE 5 MILLION SHARES SWALLOWED by whales? 52WKHIGH 10 cents 38 million VOLUME? MONEY. Did you see those MASSIVE BULK SMACKS on the ask?. 670k buy just went through 40 minutes ago. Massive hits. RDGL will break its 10 cent 52 week high. TOO MANY WHALES IN THE WATER NOW. LIQUIDDDDD TINY FLOAT.
isopet results show effective in killing cancer in cats. ONLY 81 MILLION O\S. Thin to multipennies. Will not be down here for long.
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
$RDGL HAS VIRAL WRITTEN ALL OVER IT. Its comical when I hear someone say "going to trips" that DEFINITELY makes me want to faint. ARE YOU SEEIN THE GEY FLOWING IN HERE? I've seen stocks go from cents to dollars with far less ISO pet cures has been proven to be effective in cancer for cats do you understand what this means doesn't even need human trials just from the cats alone is veterinarians dream. THE EXPOSURE TO RGDL can't be taken back. THE FACTS Can't be unseen, its Effectiveness in dogs in one experiment and in cats and the money that has been flowing in here will make this break its 52 week high or $0.10 you are ignoring $0.01 your $0.01 can be $0.08 in a Flash nothing can hold this down the group dumping they're going to miss out.
GOING TO TRIPS???! WITH THIS FLOAT AND INSIDER OWNERSHIP? Please tell me more jokes
$RDGL OMG DID U SEE 5 MILLION SHARES SWALLOWED IN 2 HOURS?52WKHIGH 10 cents Did you see those MASSIVE BULK SMACKS on the ask?. 670k buy just went through 40 minutes ago. Massive hits. RDGL will break its 10 cent 52 week high. TOO MANY WHALES IN THE WATER NOW. LIQUIDDDDD TINY FLOAT.
isopet results show effective in killing cancer in cats. ONLY 81 MILLION O\S. Thin to multipennies. Will not be down here for long.
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
$RDGL 011 down 30% 52WKHIGH 10 cents! Stop looking a gift horse in the mouth???? isopet results show effective in killing cancer in cats. ONLY 81 MILLION O\S. Thin to multipennies. Will not be down here for long.
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
$RDGL 011 down 30% 52WKHIGH 10 cents! Stop looking a gift horse in the mouth???? isopet results show effective in killing cancer in cats. ONLY 81 MILLION O\S. Thin to multipennies. Will not be down here for long.
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL RDGL RDGL RDGL RDGL
RDGL did you see that 670k MONSTER BUY ??! No matter how much the group tries to bring her down some whales smacking that ask with no care. I've created a MONSTER. RDGL will break that 10 cent 52 week high with this PRODUCT and FLOAT. TOO MANY BIG POCKET eyes on her now. Even 5 cents is a 500% ROI from here ...that's beyond attainable her. Look at the MONEY FLYING ALL OVER her.
RDGL here's the story. There was a group who loaded, they've been dumping ferociously planning to buy back in the subs. The problem is due to the MILLIONS of dollars that have been traded here the last 10 DAYS, the FLOAT, and most importantly the ACTUAL $DOLLAR potential UNKNOWN PRODUCT new hands are SOAKING UP EVERY SELL. There is nothing on the ask stopping RDGL from brwaking 3 cents on the L2. New ballgame here. Expect a REAL STRONG parabolic move here. RDGL has a great story for BIG BOARD "investors" you all KNOW how pharmaceutical stocks FLY. ISOPET PROVEN EFFECTIVE FOR CANCER IN CATS
RDGL the cats out the bag. Top 5 most read and most posted. Everyone is jumping in. Nothing can stop this train. I see a break of 5 cents VERY SOON. Where was everyone when I was SCREAMING about this at 003 last Monday? Hmmm?
$PPCB 038 JUST BECAUSE 99.999% OF THE WORLD NEVER HEARD OF IT, SHOULDN'T MEAN U SHOULDN'T. bouncing off 52week low of .031. 52 week high is 90 cents!
JUST BECAUSE 99.9999% OF TRADERS IN THE WHOLE WORLD haven't heard of this AUSTRALIAN CANCER BIOTECH gem doesn't mean you shouldn't. We all know that pharmaceutical stocks are the ones with the MOST POTENTIAL TO MAKE. Percentage RUNS IN THE TENS OF THOUSANDS across all markets, OTC TO NASDAQ. Now imagine the rum LOWFLIAT BIOTECHS MAKE. They are zipcode\life changers.
If you know me, you should already know. Snooze and lose. GRANTED CANCER PATENT FROM THE EU!?????
$PPCB this unknown battered\ bloodied #BIOTECH crushed down from 52 WEEK HIGH of 90 CENTS.
I'm not here to sell you a dream but this can break 10 cents in DAYS with volume. The float is that thin.
LETS TALK MATH HERE. LIKE stuff you can actually quantify and measure.
PPCB only has 38 million shares outstanding juxtaposed with over 10,0000 stocks in the OTC and it's in the .0001 percententile juxtaposed with other biotech stocks and there is no comparison its in the .000000000001 percentile. #FACT. Don't sleep?????
$PPCB Propanc Biopharma Provides Shareholder Update and Goals for 2018
PR Newswire
MELBOURNE, Australia, Feb. 12, 2018
MELBOURNE, Australia, Feb. 12, 2018 /PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced an update on the progress of the Company and its R&D activities in 2017 and its forecast for this year, as the Company looks towards commencing a First-In-Human (FIH) study for its lead product candidate, PRP, a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
Since the beginning of 2017, the Company has initiated and completed a number of activities, including:
Filed two Patent Cooperation Treaty (PCT) applications for a cancer treatment and composition of proenzymes for cancer treatment, respectively. The PCT application for a cancer treatment claims priority from two earlier Spanish patent applications filed in 2016. The PCT assists applicants in simultaneously seeking protection for an invention in over 150 countries.
Acceptance of a lead patent application for PRP from the Chinese Patent Office was received.
A GLP-Compliant toxicity study over a 28-day period was successfully completed, where no treatment related findings were observed. This concluded the preclinical development phase of PRP and provides a safety margin for a dosage of PRP to be administered in a First-In-Human study.
A method for detection of IR dye labelled trypsinogen and chymotrypsinogen in rat plasma was successfully validated. The assay was deemed to have acceptable precision and accuracy. It was also selective for the two IR dye labelled proenzymes, as opposed to the unlabelled proenzymes.
The U.S. Food and Drug Administration (the "FDA") granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.
A manufacturing process capable of purifying and stabilizing two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen were developed successfully.
A sandwich ELISA was developed for the determination of a mixture of chymotrypsinogen and trypsinogen in dose formulations and human serum. Further development work is necessary to validate the method for the analysis of the two proenzymes in human serum.
As a result of the activities completed in 2017, the Company intends to undertake the following activities:
Conduct a Scientific Advice meeting with the MHRA in order to prepare an Investigational Medicinal Dossier for PRP, which will contribute to the preparation of a Clinical Trial Application (CTA) for a First-In-Human study in advanced cancer patients with solid tumors.
Scale up GMP manufacture of PRP for human studies.
Undertake detailed analysis of the two proenzymes (trypsinogen and chymotrypsinogen) and their activated enzyme forms (trypsin and chymotrypsin) from the PRP formulation by Liquid Chromatography-Mass Spectrometry. It is believed analysis of these four analytes will provide a better understanding of the bio-distribution of PRP in human blood plasma (pharmacokinetics). The intention is to develop and validate an analytical method to measure the pharmacokinetics of PRP that will provide important information for future Phase II clinical studies in pancreatic and ovarian cancer patients.
Currently progressing towards a First-In-Human study, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharma-Provides-Shareholder-Update-and-Goals-for-2018?id=183058
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPBC
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPBC
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPBC
$PPCB 038 JUST BECAUSE 99.999% OF THE WORLD NEVER HEARD OF IT, SHOULDN'T MEAN U SHOULDN'T. bouncing off 52week low of .031. 52 week high is 90 cents!
JUST BECAUSE 99.9999% OF TRADERS IN THE WHOLE WORLD haven't heard of this AUSTRALIAN CANCER BIOTECH gem doesn't mean you shouldn't. We all know that pharmaceutical stocks are the ones with the MOST POTENTIAL TO MAKE. Percentage RUNS IN THE TENS OF THOUSANDS across all markets, OTC TO NASDAQ. Now imagine the rum LOWFLIAT BIOTECHS MAKE. They are zipcode\life changers.
If you know me, you should already know. Snooze and lose. GRANTED CANCER PATENT FROM THE EU!?????
$PPCB this unknown battered\ bloodied #BIOTECH crushed down from 52 WEEK HIGH of 90 CENTS.
I'm not here to sell you a dream but this can break 10 cents in DAYS with volume. The float is that thin.
LETS TALK MATH HERE. LIKE stuff you can actually quantify and measure.
PPCB only has 38 million shares outstanding juxtaposed with over 10,0000 stocks in the OTC and it's in the .0001 percententile juxtaposed with other biotech stocks and there is no comparison its in the .000000000001 percentile. #FACT. Don't sleep?????
$PPCB Propanc Biopharma Provides Shareholder Update and Goals for 2018
PR Newswire
MELBOURNE, Australia, Feb. 12, 2018
MELBOURNE, Australia, Feb. 12, 2018 /PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced an update on the progress of the Company and its R&D activities in 2017 and its forecast for this year, as the Company looks towards commencing a First-In-Human (FIH) study for its lead product candidate, PRP, a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
Since the beginning of 2017, the Company has initiated and completed a number of activities, including:
Filed two Patent Cooperation Treaty (PCT) applications for a cancer treatment and composition of proenzymes for cancer treatment, respectively. The PCT application for a cancer treatment claims priority from two earlier Spanish patent applications filed in 2016. The PCT assists applicants in simultaneously seeking protection for an invention in over 150 countries.
Acceptance of a lead patent application for PRP from the Chinese Patent Office was received.
A GLP-Compliant toxicity study over a 28-day period was successfully completed, where no treatment related findings were observed. This concluded the preclinical development phase of PRP and provides a safety margin for a dosage of PRP to be administered in a First-In-Human study.
A method for detection of IR dye labelled trypsinogen and chymotrypsinogen in rat plasma was successfully validated. The assay was deemed to have acceptable precision and accuracy. It was also selective for the two IR dye labelled proenzymes, as opposed to the unlabelled proenzymes.
The U.S. Food and Drug Administration (the "FDA") granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.
A manufacturing process capable of purifying and stabilizing two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen were developed successfully.
A sandwich ELISA was developed for the determination of a mixture of chymotrypsinogen and trypsinogen in dose formulations and human serum. Further development work is necessary to validate the method for the analysis of the two proenzymes in human serum.
As a result of the activities completed in 2017, the Company intends to undertake the following activities:
Conduct a Scientific Advice meeting with the MHRA in order to prepare an Investigational Medicinal Dossier for PRP, which will contribute to the preparation of a Clinical Trial Application (CTA) for a First-In-Human study in advanced cancer patients with solid tumors.
Scale up GMP manufacture of PRP for human studies.
Undertake detailed analysis of the two proenzymes (trypsinogen and chymotrypsinogen) and their activated enzyme forms (trypsin and chymotrypsin) from the PRP formulation by Liquid Chromatography-Mass Spectrometry. It is believed analysis of these four analytes will provide a better understanding of the bio-distribution of PRP in human blood plasma (pharmacokinetics). The intention is to develop and validate an analytical method to measure the pharmacokinetics of PRP that will provide important information for future Phase II clinical studies in pancreatic and ovarian cancer patients.
Currently progressing towards a First-In-Human study, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharma-Provides-Shareholder-Update-and-Goals-for-2018?id=183058
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPBC
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPBC
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPBC
$PPCB HAVE YOU EVER SEEN A #PHARMACEUTICAL stock run from cents to dollars? I have
PPCB 032 bouncing off 52week low of .031. 52 week high is 90 cents!
JUST BECAUSE 99.9999% OF TRADERS IN THE WHOLE WORLD haven't heard of this AUSTRALIAN CANCER BIOTECH gem doesn't mean you shouldn't. We all know that pharmaceutical stocks are the ones with the MOST POTENTIAL TO MAKE. Percentage RUNS IN THE TENS OF THOUSANDS across all markets, OTC TO NASDAQ. Now imagine the rum LOWFLIAT BIOTECHS MAKE. They are zipcode\life changers.
If you know me, you should already know. Snooze and lose. GRANTED CANCER PATENT FROM THE EU!?????
$PPCB this unknown battered\ bloodied #BIOTECH crushed down from 52 WEEK HIGH of 90 CENTS.
I'm not here to sell you a dream but this can break 10 cents in DAYS with volume. The float is that thin.
LETS TALK MATH HERE. LIKE stuff you can actually quantify and measure.
PPCB only has 38 million shares outstanding juxtaposed with over 10,0000 stocks in the OTC and it's in the .0001 percententile juxtaposed with other biotech stocks and there is no comparison its in the .000000000001 percentile. #FACT. Don't sleep?????
$PPCB Propanc Biopharma Provides Shareholder Update and Goals for 2018
PR Newswire
MELBOURNE, Australia, Feb. 12, 2018
MELBOURNE, Australia, Feb. 12, 2018 /PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced an update on the progress of the Company and its R&D activities in 2017 and its forecast for this year, as the Company looks towards commencing a First-In-Human (FIH) study for its lead product candidate, PRP, a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
Since the beginning of 2017, the Company has initiated and completed a number of activities, including:
Filed two Patent Cooperation Treaty (PCT) applications for a cancer treatment and composition of proenzymes for cancer treatment, respectively. The PCT application for a cancer treatment claims priority from two earlier Spanish patent applications filed in 2016. The PCT assists applicants in simultaneously seeking protection for an invention in over 150 countries.
Acceptance of a lead patent application for PRP from the Chinese Patent Office was received.
A GLP-Compliant toxicity study over a 28-day period was successfully completed, where no treatment related findings were observed. This concluded the preclinical development phase of PRP and provides a safety margin for a dosage of PRP to be administered in a First-In-Human study.
A method for detection of IR dye labelled trypsinogen and chymotrypsinogen in rat plasma was successfully validated. The assay was deemed to have acceptable precision and accuracy. It was also selective for the two IR dye labelled proenzymes, as opposed to the unlabelled proenzymes.
The U.S. Food and Drug Administration (the "FDA") granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.
A manufacturing process capable of purifying and stabilizing two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen were developed successfully.
A sandwich ELISA was developed for the determination of a mixture of chymotrypsinogen and trypsinogen in dose formulations and human serum. Further development work is necessary to validate the method for the analysis of the two proenzymes in human serum.
As a result of the activities completed in 2017, the Company intends to undertake the following activities:
Conduct a Scientific Advice meeting with the MHRA in order to prepare an Investigational Medicinal Dossier for PRP, which will contribute to the preparation of a Clinical Trial Application (CTA) for a First-In-Human study in advanced cancer patients with solid tumors.
Scale up GMP manufacture of PRP for human studies.
Undertake detailed analysis of the two proenzymes (trypsinogen and chymotrypsinogen) and their activated enzyme forms (trypsin and chymotrypsin) from the PRP formulation by Liquid Chromatography-Mass Spectrometry. It is believed analysis of these four analytes will provide a better understanding of the bio-distribution of PRP in human blood plasma (pharmacokinetics). The intention is to develop and validate an analytical method to measure the pharmacokinetics of PRP that will provide important information for future Phase II clinical studies in pancreatic and ovarian cancer patients.
Currently progressing towards a First-In-Human study, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharma-Provides-Shareholder-Update-and-Goals-for-2018?id=183058
PPBC PPCB PPBC PPBC PPBC PPBC PPBC PPBC PPBC PPBC
PPBC PPCB PPBC PPBC PPBC PPBC PPBC PPBC PPBC PPBC
$PPCB HAVE YOU EVER SEEN A #PHARMACEUTICAL stock run from cents to dollars? I have
PPCB 032 bouncing off 52week low of .031. 52 week high is 90 cents!
JUST BECAUSE 99.9999% OF TRADERS IN THE WHOLE WORLD haven't heard of this AUSTRALIAN CANCER BIOTECH gem doesn't mean you shouldn't. We all know that pharmaceutical stocks are the ones with the MOST POTENTIAL TO MAKE. Percentage RUNS IN THE TENS OF THOUSANDS across all markets, OTC TO NASDAQ. Now imagine the rum LOWFLIAT BIOTECHS MAKE. They are zipcode\life changers.
If you know me, you should already know. Snooze and lose. GRANTED CANCER PATENT FROM THE EU!?????
$PPCB this unknown battered\ bloodied #BIOTECH crushed down from 52 WEEK HIGH of 90 CENTS.
I'm not here to sell you a dream but this can break 10 cents in DAYS with volume. The float is that thin.
LETS TALK MATH HERE. LIKE stuff you can actually quantify and measure.
PPCB only has 38 million shares outstanding juxtaposed with over 10,0000 stocks in the OTC and it's in the .0001 percententile juxtaposed with other biotech stocks and there is no comparison its in the .000000000001 percentile. #FACT. Don't sleep?????
$PPCB Propanc Biopharma Provides Shareholder Update and Goals for 2018
PR Newswire
MELBOURNE, Australia, Feb. 12, 2018
MELBOURNE, Australia, Feb. 12, 2018 /PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced an update on the progress of the Company and its R&D activities in 2017 and its forecast for this year, as the Company looks towards commencing a First-In-Human (FIH) study for its lead product candidate, PRP, a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
Since the beginning of 2017, the Company has initiated and completed a number of activities, including:
Filed two Patent Cooperation Treaty (PCT) applications for a cancer treatment and composition of proenzymes for cancer treatment, respectively. The PCT application for a cancer treatment claims priority from two earlier Spanish patent applications filed in 2016. The PCT assists applicants in simultaneously seeking protection for an invention in over 150 countries.
Acceptance of a lead patent application for PRP from the Chinese Patent Office was received.
A GLP-Compliant toxicity study over a 28-day period was successfully completed, where no treatment related findings were observed. This concluded the preclinical development phase of PRP and provides a safety margin for a dosage of PRP to be administered in a First-In-Human study.
A method for detection of IR dye labelled trypsinogen and chymotrypsinogen in rat plasma was successfully validated. The assay was deemed to have acceptable precision and accuracy. It was also selective for the two IR dye labelled proenzymes, as opposed to the unlabelled proenzymes.
The U.S. Food and Drug Administration (the "FDA") granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.
A manufacturing process capable of purifying and stabilizing two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen were developed successfully.
A sandwich ELISA was developed for the determination of a mixture of chymotrypsinogen and trypsinogen in dose formulations and human serum. Further development work is necessary to validate the method for the analysis of the two proenzymes in human serum.
As a result of the activities completed in 2017, the Company intends to undertake the following activities:
Conduct a Scientific Advice meeting with the MHRA in order to prepare an Investigational Medicinal Dossier for PRP, which will contribute to the preparation of a Clinical Trial Application (CTA) for a First-In-Human study in advanced cancer patients with solid tumors.
Scale up GMP manufacture of PRP for human studies.
Undertake detailed analysis of the two proenzymes (trypsinogen and chymotrypsinogen) and their activated enzyme forms (trypsin and chymotrypsin) from the PRP formulation by Liquid Chromatography-Mass Spectrometry. It is believed analysis of these four analytes will provide a better understanding of the bio-distribution of PRP in human blood plasma (pharmacokinetics). The intention is to develop and validate an analytical method to measure the pharmacokinetics of PRP that will provide important information for future Phase II clinical studies in pancreatic and ovarian cancer patients.
Currently progressing towards a First-In-Human study, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharma-Provides-Shareholder-Update-and-Goals-for-2018?id=183058
PPBC PPCB PPBC PPBC PPBC PPBC PPBC PPBC PPBC PPBC
PPBC PPCB PPBC PPBC PPBC PPBC PPBC PPBC PPBC PPBC
$PPBC .034 NOTHING WILL STOP THIS BIOTECH TRAIN!! Its not my problem if you never heard of it. JUST GRANTED AN EU PATENT. ONLY 38 MILLION O\S at 035???!!! #BIOTECH??!!
52 WEEK HIGH 90 CENTS. Based in Australia reason its unknown to American traders. Grab your TELESCOPE I'll save to you.
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials
Purification Process Achieves Pure and Stable Active Drug Substances, Engineering Runs to Commence
PR Newswire
MELBOURNE, Australia, Dec. 4, 2017
MELBOURNE, Australia, Dec. 4, 2017/PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has made significant recent progress towards full scale Good Manufacturing Process (GMP) manufacture of its lead product, PRP, for First-In-Human studies, expected to commence in 2018. Research and development activities conducted with its European Contract Manufacturing Organization (CMO) experienced in the production of biopharmaceuticals, have been successful in developing a process capable of purifying and stabilizing the two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen, which is an important requirement during the manufacturing process. As a result, the Company is set to commence engineering runs of manufacturing the finished drug product, prior to full scale GMP manufacture of PRP for human trials. PRP is a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
"We are delighted with the excellent progress made with our CMO in progressing PRP to its current stage of development and we are excited about our plans to move into First-In-Human studies next year," said Dr Julian Kenyon, Propanc Biopharma's Chief Scientific Officer. "Purifying and stabilizing each active drug substance of PRP has been technically challenging. This is due to the nature of the proenzymes which are able to auto-activate themselves, which is not unexpected for biological molecules of this nature. The work conducted by our research and development team to meet this challenge has been first class and we look forward to progressing PRP through to clinical development."
The Company expects to file its first Clinical Trial Application (CTA) for a First-In-Human study in the UK next year, initially treating late stage cancer patients with solid tumors, before progressing into two larger Phase II Proof of Concept studies in both pancreatic and ovarian cancer patients. Preclinical animal studies demonstrating proof of concept, in vivo, as well as the completion of a GLP-compliant, 28-day repeat-dose toxicology study, which helps to confirm the starting dose in humans by identifying the No Observable Adverse Effect Level (NOAEL) in an animal species, has the management team confident it has undertaken the steps necessary to achieve the best possible results in its planned human studies. This is further supported by the FDA granting Orphan Drug Designation of PRP for the treatment of one of its lead indications, pancreatic cancer, with a second application filed for ovarian cancer under evaluation.
"I am pleased with the progress of PRP and look forward to preparing our lead product for First-In-Human studies next year," said Professor Klaus Kutz, Propanc Biopharma's Chief Medical Officer. "The Company has undertaken significant work to prepare for this important milestone, and believe the product can benefit patients suffering from aggressive solid tumors, which are most often incurable. Extending life meaningfully, but without compromising the quality of life for patients, without the side effects normally associated with standard treatment regimens, remains a high priority. We remain hopeful that PRP can become a breakthrough product for many patients worldwide."
Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPBC .034 NOTHING WILL STOP THIS BIOTECH TRAIN!! Its not my problem if you never heard of it. JUST GRANTED AN EU PATENT. ONLY 38 MILLION O\S at 035???!!! #BIOTECH??!!
52 WEEK HIGH 90 CENTS. Based in Australia reason its unknown to American traders. Grab your TELESCOPE I'll save to you.
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials
Purification Process Achieves Pure and Stable Active Drug Substances, Engineering Runs to Commence
PR Newswire
MELBOURNE, Australia, Dec. 4, 2017
MELBOURNE, Australia, Dec. 4, 2017/PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has made significant recent progress towards full scale Good Manufacturing Process (GMP) manufacture of its lead product, PRP, for First-In-Human studies, expected to commence in 2018. Research and development activities conducted with its European Contract Manufacturing Organization (CMO) experienced in the production of biopharmaceuticals, have been successful in developing a process capable of purifying and stabilizing the two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen, which is an important requirement during the manufacturing process. As a result, the Company is set to commence engineering runs of manufacturing the finished drug product, prior to full scale GMP manufacture of PRP for human trials. PRP is a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
"We are delighted with the excellent progress made with our CMO in progressing PRP to its current stage of development and we are excited about our plans to move into First-In-Human studies next year," said Dr Julian Kenyon, Propanc Biopharma's Chief Scientific Officer. "Purifying and stabilizing each active drug substance of PRP has been technically challenging. This is due to the nature of the proenzymes which are able to auto-activate themselves, which is not unexpected for biological molecules of this nature. The work conducted by our research and development team to meet this challenge has been first class and we look forward to progressing PRP through to clinical development."
The Company expects to file its first Clinical Trial Application (CTA) for a First-In-Human study in the UK next year, initially treating late stage cancer patients with solid tumors, before progressing into two larger Phase II Proof of Concept studies in both pancreatic and ovarian cancer patients. Preclinical animal studies demonstrating proof of concept, in vivo, as well as the completion of a GLP-compliant, 28-day repeat-dose toxicology study, which helps to confirm the starting dose in humans by identifying the No Observable Adverse Effect Level (NOAEL) in an animal species, has the management team confident it has undertaken the steps necessary to achieve the best possible results in its planned human studies. This is further supported by the FDA granting Orphan Drug Designation of PRP for the treatment of one of its lead indications, pancreatic cancer, with a second application filed for ovarian cancer under evaluation.
"I am pleased with the progress of PRP and look forward to preparing our lead product for First-In-Human studies next year," said Professor Klaus Kutz, Propanc Biopharma's Chief Medical Officer. "The Company has undertaken significant work to prepare for this important milestone, and believe the product can benefit patients suffering from aggressive solid tumors, which are most often incurable. Extending life meaningfully, but without compromising the quality of life for patients, without the side effects normally associated with standard treatment regimens, remains a high priority. We remain hopeful that PRP can become a breakthrough product for many patients worldwide."
Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPCB 52-week-low 033?! 52WKH 90 cents! #biotech Shorts Decreased by 93%
PROPANC BIOPHARMA INC (OTCMKTS:PPCB) Shorts Decreased by 93% After Short Covering THIS BIOTECH GEM IS UNKNOWN. ONLY 38 MILLION O\S. I REPEAT ONLY 38 MILLION O\S. Won't be unknown for long
Propanc Biopharma, Inc., a development stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. The company has market cap of $1.86 million. The companyÂ’s lead product includes PRP, a patented formulation consisting of two pro-enzymes, such as trypsinogen and chymotrypsinogen, as well as the enzyme amylase designed to synergistically enhance anti-cancer effects. It currently has negative earnings. It is also developing a combination of anti-cancer agents working in combination with pro-enzymes, which enhance PRPÂ’s anti-cancer effects.
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPCB 52-week-low 033?! 52WKH 90 cents! #biotech Shorts Decreased by 93%
PROPANC BIOPHARMA INC (OTCMKTS:PPCB) Shorts Decreased by 93% After Short Covering THIS BIOTECH GEM IS UNKNOWN. ONLY 38 MILLION O\S. I REPEAT ONLY 38 MILLION O\S. Won't be unknown for long
Propanc Biopharma, Inc., a development stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. The company has market cap of $1.86 million. The companyÂ’s lead product includes PRP, a patented formulation consisting of two pro-enzymes, such as trypsinogen and chymotrypsinogen, as well as the enzyme amylase designed to synergistically enhance anti-cancer effects. It currently has negative earnings. It is also developing a combination of anti-cancer agents working in combination with pro-enzymes, which enhance PRPÂ’s anti-cancer effects.
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPCB 52-week-low 033?! 52WKH 90 cents! #biotech Shorts Decreased by 93%
PROPANC BIOPHARMA INC (OTCMKTS:PPCB) Shorts Decreased by 93% After Short Covering THIS BIOTECH GEM IS UNKNOWN. ONLY 38 MILLION O\S. I REPEAT ONLY 38 MILLION O\S. Won't be unknown for long
Propanc Biopharma, Inc., a development stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. The company has market cap of $1.86 million. The companyÂ’s lead product includes PRP, a patented formulation consisting of two pro-enzymes, such as trypsinogen and chymotrypsinogen, as well as the enzyme amylase designed to synergistically enhance anti-cancer effects. It currently has negative earnings. It is also developing a combination of anti-cancer agents working in combination with pro-enzymes, which enhance PRPÂ’s anti-cancer effects.
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPBC .034 NOTHING WILL STOP THIS BIOTECH TRAIN!! Its not my problem if you never heard of it. JUST GRANTED AN EU PATENT. ONLY 38 MILLION O\S at 035???!!! #BIOTECH??!!
52 WEEK HIGH 90 CENTS. Based in Australia reason its unknown to American traders. Grab your TELESCOPE I'll save to you.
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials
Purification Process Achieves Pure and Stable Active Drug Substances, Engineering Runs to Commence
PR Newswire
MELBOURNE, Australia, Dec. 4, 2017
MELBOURNE, Australia, Dec. 4, 2017/PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has made significant recent progress towards full scale Good Manufacturing Process (GMP) manufacture of its lead product, PRP, for First-In-Human studies, expected to commence in 2018. Research and development activities conducted with its European Contract Manufacturing Organization (CMO) experienced in the production of biopharmaceuticals, have been successful in developing a process capable of purifying and stabilizing the two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen, which is an important requirement during the manufacturing process. As a result, the Company is set to commence engineering runs of manufacturing the finished drug product, prior to full scale GMP manufacture of PRP for human trials. PRP is a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
"We are delighted with the excellent progress made with our CMO in progressing PRP to its current stage of development and we are excited about our plans to move into First-In-Human studies next year," said Dr Julian Kenyon, Propanc Biopharma's Chief Scientific Officer. "Purifying and stabilizing each active drug substance of PRP has been technically challenging. This is due to the nature of the proenzymes which are able to auto-activate themselves, which is not unexpected for biological molecules of this nature. The work conducted by our research and development team to meet this challenge has been first class and we look forward to progressing PRP through to clinical development."
The Company expects to file its first Clinical Trial Application (CTA) for a First-In-Human study in the UK next year, initially treating late stage cancer patients with solid tumors, before progressing into two larger Phase II Proof of Concept studies in both pancreatic and ovarian cancer patients. Preclinical animal studies demonstrating proof of concept, in vivo, as well as the completion of a GLP-compliant, 28-day repeat-dose toxicology study, which helps to confirm the starting dose in humans by identifying the No Observable Adverse Effect Level (NOAEL) in an animal species, has the management team confident it has undertaken the steps necessary to achieve the best possible results in its planned human studies. This is further supported by the FDA granting Orphan Drug Designation of PRP for the treatment of one of its lead indications, pancreatic cancer, with a second application filed for ovarian cancer under evaluation.
"I am pleased with the progress of PRP and look forward to preparing our lead product for First-In-Human studies next year," said Professor Klaus Kutz, Propanc Biopharma's Chief Medical Officer. "The Company has undertaken significant work to prepare for this important milestone, and believe the product can benefit patients suffering from aggressive solid tumors, which are most often incurable. Extending life meaningfully, but without compromising the quality of life for patients, without the side effects normally associated with standard treatment regimens, remains a high priority. We remain hopeful that PRP can become a breakthrough product for many patients worldwide."
Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPBC .034 NOTHING WILL STOP THIS BIOTECH TRAIN!! Its not my problem if you never heard of it. JUST GRANTED AN EU PATENT. ONLY 38 MILLION O\S at 035???!!! #BIOTECH??!!
52 WEEK HIGH 90 CENTS. Based in Australia reason its unknown to American traders. Grab your TELESCOPE I'll save to you.
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials
Purification Process Achieves Pure and Stable Active Drug Substances, Engineering Runs to Commence
PR Newswire
MELBOURNE, Australia, Dec. 4, 2017
MELBOURNE, Australia, Dec. 4, 2017/PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has made significant recent progress towards full scale Good Manufacturing Process (GMP) manufacture of its lead product, PRP, for First-In-Human studies, expected to commence in 2018. Research and development activities conducted with its European Contract Manufacturing Organization (CMO) experienced in the production of biopharmaceuticals, have been successful in developing a process capable of purifying and stabilizing the two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen, which is an important requirement during the manufacturing process. As a result, the Company is set to commence engineering runs of manufacturing the finished drug product, prior to full scale GMP manufacture of PRP for human trials. PRP is a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
"We are delighted with the excellent progress made with our CMO in progressing PRP to its current stage of development and we are excited about our plans to move into First-In-Human studies next year," said Dr Julian Kenyon, Propanc Biopharma's Chief Scientific Officer. "Purifying and stabilizing each active drug substance of PRP has been technically challenging. This is due to the nature of the proenzymes which are able to auto-activate themselves, which is not unexpected for biological molecules of this nature. The work conducted by our research and development team to meet this challenge has been first class and we look forward to progressing PRP through to clinical development."
The Company expects to file its first Clinical Trial Application (CTA) for a First-In-Human study in the UK next year, initially treating late stage cancer patients with solid tumors, before progressing into two larger Phase II Proof of Concept studies in both pancreatic and ovarian cancer patients. Preclinical animal studies demonstrating proof of concept, in vivo, as well as the completion of a GLP-compliant, 28-day repeat-dose toxicology study, which helps to confirm the starting dose in humans by identifying the No Observable Adverse Effect Level (NOAEL) in an animal species, has the management team confident it has undertaken the steps necessary to achieve the best possible results in its planned human studies. This is further supported by the FDA granting Orphan Drug Designation of PRP for the treatment of one of its lead indications, pancreatic cancer, with a second application filed for ovarian cancer under evaluation.
"I am pleased with the progress of PRP and look forward to preparing our lead product for First-In-Human studies next year," said Professor Klaus Kutz, Propanc Biopharma's Chief Medical Officer. "The Company has undertaken significant work to prepare for this important milestone, and believe the product can benefit patients suffering from aggressive solid tumors, which are most often incurable. Extending life meaningfully, but without compromising the quality of life for patients, without the side effects normally associated with standard treatment regimens, remains a high priority. We remain hopeful that PRP can become a breakthrough product for many patients worldwide."
Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPBC .033 UNKNOWN AUSTRALIAN BIOTECH DOWN FROM 90 CENTS. 20 CENTS OR BUST
Propanc Biopharma Completes Successful Reproduction Run for PRP
Company Requests Scientific Advice Meeting with the MHRA (UK) to Discuss Next Steps
https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharma-Completes-Successful-Reproduction-Run-for-PRP?id=186107
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPBC .033 UNKNOWN AUSTRALIAN BIOTECH DOWN FROM 90 CENTS. 20 CENTS OR BUST
Propanc Biopharma Completes Successful Reproduction Run for PRP
Company Requests Scientific Advice Meeting with the MHRA (UK) to Discuss Next Steps
https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharma-Completes-Successful-Reproduction-Run-for-PRP?id=186107
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPCB HAVE YOU EVER SEEN A #PHARMACEUTICAL stock run from cents to dollars? I have
PPCB 032 bouncing off 52week low of .031. 52 week high is 90 cents!
JUST BECAUSE 99.9999% OF TRADERS IN THE WHOLE WORLD haven't heard of this AUSTRALIAN CANCER BIOTECH gem doesn't mean you shouldn't. We all know that pharmaceutical stocks are the ones with the MOST POTENTIAL TO MAKE. Percentage RUNS IN THE TENS OF THOUSANDS across all markets, OTC TO NASDAQ. Now imagine the rum LOWFLIAT BIOTECHS MAKE. They are zipcode\life changers.
If you know me, you should already know. Snooze and lose. GRANTED CANCER PATENT FROM THE EU!?????
$PPCB this unknown battered\ bloodied #BIOTECH crushed down from 52 WEEK HIGH of 90 CENTS.
I'm not here to sell you a dream but this can break 10 cents in DAYS with volume. The float is that thin.
LETS TALK MATH HERE. LIKE stuff you can actually quantify and measure.
PPCB only has 38 million shares outstanding juxtaposed with over 10,0000 stocks in the OTC and it's in the .0001 percententile juxtaposed with other biotech stocks and there is no comparison its in the .000000000001 percentile. #FACT. Don't sleep?????
$PPCB Propanc Biopharma Provides Shareholder Update and Goals for 2018
PR Newswire
MELBOURNE, Australia, Feb. 12, 2018
MELBOURNE, Australia, Feb. 12, 2018 /PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced an update on the progress of the Company and its R&D activities in 2017 and its forecast for this year, as the Company looks towards commencing a First-In-Human (FIH) study for its lead product candidate, PRP, a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
Since the beginning of 2017, the Company has initiated and completed a number of activities, including:
Filed two Patent Cooperation Treaty (PCT) applications for a cancer treatment and composition of proenzymes for cancer treatment, respectively. The PCT application for a cancer treatment claims priority from two earlier Spanish patent applications filed in 2016. The PCT assists applicants in simultaneously seeking protection for an invention in over 150 countries.
Acceptance of a lead patent application for PRP from the Chinese Patent Office was received.
A GLP-Compliant toxicity study over a 28-day period was successfully completed, where no treatment related findings were observed. This concluded the preclinical development phase of PRP and provides a safety margin for a dosage of PRP to be administered in a First-In-Human study.
A method for detection of IR dye labelled trypsinogen and chymotrypsinogen in rat plasma was successfully validated. The assay was deemed to have acceptable precision and accuracy. It was also selective for the two IR dye labelled proenzymes, as opposed to the unlabelled proenzymes.
The U.S. Food and Drug Administration (the "FDA") granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.
A manufacturing process capable of purifying and stabilizing two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen were developed successfully.
A sandwich ELISA was developed for the determination of a mixture of chymotrypsinogen and trypsinogen in dose formulations and human serum. Further development work is necessary to validate the method for the analysis of the two proenzymes in human serum.
As a result of the activities completed in 2017, the Company intends to undertake the following activities:
Conduct a Scientific Advice meeting with the MHRA in order to prepare an Investigational Medicinal Dossier for PRP, which will contribute to the preparation of a Clinical Trial Application (CTA) for a First-In-Human study in advanced cancer patients with solid tumors.
Scale up GMP manufacture of PRP for human studies.
Undertake detailed analysis of the two proenzymes (trypsinogen and chymotrypsinogen) and their activated enzyme forms (trypsin and chymotrypsin) from the PRP formulation by Liquid Chromatography-Mass Spectrometry. It is believed analysis of these four analytes will provide a better understanding of the bio-distribution of PRP in human blood plasma (pharmacokinetics). The intention is to develop and validate an analytical method to measure the pharmacokinetics of PRP that will provide important information for future Phase II clinical studies in pancreatic and ovarian cancer patients.
Currently progressing towards a First-In-Human study, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharma-Provides-Shareholder-Update-and-Goals-for-2018?id=183058
PPBC PPCB PPBC PPBC PPBC PPBC PPBC PPBC PPBC PPBC
PPBC PPCB PPBC PPBC PPBC PPBC PPBC PPBC PPBC PPBC
$PPCB HAVE YOU EVER SEEN A #PHARMACEUTICAL stock run from cents to dollars? I have
PPCB 032 bouncing off 52week low of .031. 52 week high is 90 cents!
JUST BECAUSE 99.9999% OF TRADERS IN THE WHOLE WORLD haven't heard of this AUSTRALIAN CANCER BIOTECH gem doesn't mean you shouldn't. We all know that pharmaceutical stocks are the ones with the MOST POTENTIAL TO MAKE. Percentage RUNS IN THE TENS OF THOUSANDS across all markets, OTC TO NASDAQ. Now imagine the rum LOWFLIAT BIOTECHS MAKE. They are zipcode\life changers.
If you know me, you should already know. Snooze and lose. GRANTED CANCER PATENT FROM THE EU!?????
$PPCB this unknown battered\ bloodied #BIOTECH crushed down from 52 WEEK HIGH of 90 CENTS.
I'm not here to sell you a dream but this can break 10 cents in DAYS with volume. The float is that thin.
LETS TALK MATH HERE. LIKE stuff you can actually quantify and measure.
PPCB only has 38 million shares outstanding juxtaposed with over 10,0000 stocks in the OTC and it's in the .0001 percententile juxtaposed with other biotech stocks and there is no comparison its in the .000000000001 percentile. #FACT. Don't sleep?????
$PPCB Propanc Biopharma Provides Shareholder Update and Goals for 2018
PR Newswire
MELBOURNE, Australia, Feb. 12, 2018
MELBOURNE, Australia, Feb. 12, 2018 /PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced an update on the progress of the Company and its R&D activities in 2017 and its forecast for this year, as the Company looks towards commencing a First-In-Human (FIH) study for its lead product candidate, PRP, a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
Since the beginning of 2017, the Company has initiated and completed a number of activities, including:
Filed two Patent Cooperation Treaty (PCT) applications for a cancer treatment and composition of proenzymes for cancer treatment, respectively. The PCT application for a cancer treatment claims priority from two earlier Spanish patent applications filed in 2016. The PCT assists applicants in simultaneously seeking protection for an invention in over 150 countries.
Acceptance of a lead patent application for PRP from the Chinese Patent Office was received.
A GLP-Compliant toxicity study over a 28-day period was successfully completed, where no treatment related findings were observed. This concluded the preclinical development phase of PRP and provides a safety margin for a dosage of PRP to be administered in a First-In-Human study.
A method for detection of IR dye labelled trypsinogen and chymotrypsinogen in rat plasma was successfully validated. The assay was deemed to have acceptable precision and accuracy. It was also selective for the two IR dye labelled proenzymes, as opposed to the unlabelled proenzymes.
The U.S. Food and Drug Administration (the "FDA") granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.
A manufacturing process capable of purifying and stabilizing two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen were developed successfully.
A sandwich ELISA was developed for the determination of a mixture of chymotrypsinogen and trypsinogen in dose formulations and human serum. Further development work is necessary to validate the method for the analysis of the two proenzymes in human serum.
As a result of the activities completed in 2017, the Company intends to undertake the following activities:
Conduct a Scientific Advice meeting with the MHRA in order to prepare an Investigational Medicinal Dossier for PRP, which will contribute to the preparation of a Clinical Trial Application (CTA) for a First-In-Human study in advanced cancer patients with solid tumors.
Scale up GMP manufacture of PRP for human studies.
Undertake detailed analysis of the two proenzymes (trypsinogen and chymotrypsinogen) and their activated enzyme forms (trypsin and chymotrypsin) from the PRP formulation by Liquid Chromatography-Mass Spectrometry. It is believed analysis of these four analytes will provide a better understanding of the bio-distribution of PRP in human blood plasma (pharmacokinetics). The intention is to develop and validate an analytical method to measure the pharmacokinetics of PRP that will provide important information for future Phase II clinical studies in pancreatic and ovarian cancer patients.
Currently progressing towards a First-In-Human study, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharma-Provides-Shareholder-Update-and-Goals-for-2018?id=183058
PPBC PPCB PPBC PPBC PPBC PPBC PPBC PPBC PPBC PPBC
PPBC PPCB PPBC PPBC PPBC PPBC PPBC PPBC PPBC PPBC
$PPBC .034 NOTHING WILL STOP THIS BIOTECH TRAIN!! Its not my problem if you never heard of it. JUST GRANTED AN EU PATENT. ONLY 38 MILLION O\S at 035???!!! #BIOTECH??!!
52 WEEK HIGH 90 CENTS. Based in Australia reason its unknown to American traders. Grab your TELESCOPE I'll save to you.
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials
Purification Process Achieves Pure and Stable Active Drug Substances, Engineering Runs to Commence
PR Newswire
MELBOURNE, Australia, Dec. 4, 2017
MELBOURNE, Australia, Dec. 4, 2017/PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has made significant recent progress towards full scale Good Manufacturing Process (GMP) manufacture of its lead product, PRP, for First-In-Human studies, expected to commence in 2018. Research and development activities conducted with its European Contract Manufacturing Organization (CMO) experienced in the production of biopharmaceuticals, have been successful in developing a process capable of purifying and stabilizing the two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen, which is an important requirement during the manufacturing process. As a result, the Company is set to commence engineering runs of manufacturing the finished drug product, prior to full scale GMP manufacture of PRP for human trials. PRP is a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
"We are delighted with the excellent progress made with our CMO in progressing PRP to its current stage of development and we are excited about our plans to move into First-In-Human studies next year," said Dr Julian Kenyon, Propanc Biopharma's Chief Scientific Officer. "Purifying and stabilizing each active drug substance of PRP has been technically challenging. This is due to the nature of the proenzymes which are able to auto-activate themselves, which is not unexpected for biological molecules of this nature. The work conducted by our research and development team to meet this challenge has been first class and we look forward to progressing PRP through to clinical development."
The Company expects to file its first Clinical Trial Application (CTA) for a First-In-Human study in the UK next year, initially treating late stage cancer patients with solid tumors, before progressing into two larger Phase II Proof of Concept studies in both pancreatic and ovarian cancer patients. Preclinical animal studies demonstrating proof of concept, in vivo, as well as the completion of a GLP-compliant, 28-day repeat-dose toxicology study, which helps to confirm the starting dose in humans by identifying the No Observable Adverse Effect Level (NOAEL) in an animal species, has the management team confident it has undertaken the steps necessary to achieve the best possible results in its planned human studies. This is further supported by the FDA granting Orphan Drug Designation of PRP for the treatment of one of its lead indications, pancreatic cancer, with a second application filed for ovarian cancer under evaluation.
"I am pleased with the progress of PRP and look forward to preparing our lead product for First-In-Human studies next year," said Professor Klaus Kutz, Propanc Biopharma's Chief Medical Officer. "The Company has undertaken significant work to prepare for this important milestone, and believe the product can benefit patients suffering from aggressive solid tumors, which are most often incurable. Extending life meaningfully, but without compromising the quality of life for patients, without the side effects normally associated with standard treatment regimens, remains a high priority. We remain hopeful that PRP can become a breakthrough product for many patients worldwide."
Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPBC .034 NOTHING WILL STOP THIS BIOTECH TRAIN!! Its not my problem if you never heard of it. JUST GRANTED AN EU PATENT. ONLY 38 MILLION O\S at 035???!!! #BIOTECH??!!
52 WEEK HIGH 90 CENTS. Based in Australia reason its unknown to American traders. Grab your TELESCOPE I'll save to you.
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials
Purification Process Achieves Pure and Stable Active Drug Substances, Engineering Runs to Commence
PR Newswire
MELBOURNE, Australia, Dec. 4, 2017
MELBOURNE, Australia, Dec. 4, 2017/PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has made significant recent progress towards full scale Good Manufacturing Process (GMP) manufacture of its lead product, PRP, for First-In-Human studies, expected to commence in 2018. Research and development activities conducted with its European Contract Manufacturing Organization (CMO) experienced in the production of biopharmaceuticals, have been successful in developing a process capable of purifying and stabilizing the two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen, which is an important requirement during the manufacturing process. As a result, the Company is set to commence engineering runs of manufacturing the finished drug product, prior to full scale GMP manufacture of PRP for human trials. PRP is a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
"We are delighted with the excellent progress made with our CMO in progressing PRP to its current stage of development and we are excited about our plans to move into First-In-Human studies next year," said Dr Julian Kenyon, Propanc Biopharma's Chief Scientific Officer. "Purifying and stabilizing each active drug substance of PRP has been technically challenging. This is due to the nature of the proenzymes which are able to auto-activate themselves, which is not unexpected for biological molecules of this nature. The work conducted by our research and development team to meet this challenge has been first class and we look forward to progressing PRP through to clinical development."
The Company expects to file its first Clinical Trial Application (CTA) for a First-In-Human study in the UK next year, initially treating late stage cancer patients with solid tumors, before progressing into two larger Phase II Proof of Concept studies in both pancreatic and ovarian cancer patients. Preclinical animal studies demonstrating proof of concept, in vivo, as well as the completion of a GLP-compliant, 28-day repeat-dose toxicology study, which helps to confirm the starting dose in humans by identifying the No Observable Adverse Effect Level (NOAEL) in an animal species, has the management team confident it has undertaken the steps necessary to achieve the best possible results in its planned human studies. This is further supported by the FDA granting Orphan Drug Designation of PRP for the treatment of one of its lead indications, pancreatic cancer, with a second application filed for ovarian cancer under evaluation.
"I am pleased with the progress of PRP and look forward to preparing our lead product for First-In-Human studies next year," said Professor Klaus Kutz, Propanc Biopharma's Chief Medical Officer. "The Company has undertaken significant work to prepare for this important milestone, and believe the product can benefit patients suffering from aggressive solid tumors, which are most often incurable. Extending life meaningfully, but without compromising the quality of life for patients, without the side effects normally associated with standard treatment regimens, remains a high priority. We remain hopeful that PRP can become a breakthrough product for many patients worldwide."
Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPCB 038 JUST BECAUSE 99.999% OF THE WORLD NEVER HEARD OF IT, SHOULDN'T MEAN U SHOULDN'T. bouncing off 52week low of .031. 52 week high is 90 cents!
JUST BECAUSE 99.9999% OF TRADERS IN THE WHOLE WORLD haven't heard of this AUSTRALIAN CANCER BIOTECH gem doesn't mean you shouldn't. We all know that pharmaceutical stocks are the ones with the MOST POTENTIAL TO MAKE. Percentage RUNS IN THE TENS OF THOUSANDS across all markets, OTC TO NASDAQ. Now imagine the rum LOWFLIAT BIOTECHS MAKE. They are zipcode\life changers.
If you know me, you should already know. Snooze and lose. GRANTED CANCER PATENT FROM THE EU!?????
$PPCB this unknown battered\ bloodied #BIOTECH crushed down from 52 WEEK HIGH of 90 CENTS.
I'm not here to sell you a dream but this can break 10 cents in DAYS with volume. The float is that thin.
LETS TALK MATH HERE. LIKE stuff you can actually quantify and measure.
PPCB only has 38 million shares outstanding juxtaposed with over 10,0000 stocks in the OTC and it's in the .0001 percententile juxtaposed with other biotech stocks and there is no comparison its in the .000000000001 percentile. #FACT. Don't sleep?????
$PPCB Propanc Biopharma Provides Shareholder Update and Goals for 2018
PR Newswire
MELBOURNE, Australia, Feb. 12, 2018
MELBOURNE, Australia, Feb. 12, 2018 /PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced an update on the progress of the Company and its R&D activities in 2017 and its forecast for this year, as the Company looks towards commencing a First-In-Human (FIH) study for its lead product candidate, PRP, a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
Since the beginning of 2017, the Company has initiated and completed a number of activities, including:
Filed two Patent Cooperation Treaty (PCT) applications for a cancer treatment and composition of proenzymes for cancer treatment, respectively. The PCT application for a cancer treatment claims priority from two earlier Spanish patent applications filed in 2016. The PCT assists applicants in simultaneously seeking protection for an invention in over 150 countries.
Acceptance of a lead patent application for PRP from the Chinese Patent Office was received.
A GLP-Compliant toxicity study over a 28-day period was successfully completed, where no treatment related findings were observed. This concluded the preclinical development phase of PRP and provides a safety margin for a dosage of PRP to be administered in a First-In-Human study.
A method for detection of IR dye labelled trypsinogen and chymotrypsinogen in rat plasma was successfully validated. The assay was deemed to have acceptable precision and accuracy. It was also selective for the two IR dye labelled proenzymes, as opposed to the unlabelled proenzymes.
The U.S. Food and Drug Administration (the "FDA") granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.
A manufacturing process capable of purifying and stabilizing two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen were developed successfully.
A sandwich ELISA was developed for the determination of a mixture of chymotrypsinogen and trypsinogen in dose formulations and human serum. Further development work is necessary to validate the method for the analysis of the two proenzymes in human serum.
As a result of the activities completed in 2017, the Company intends to undertake the following activities:
Conduct a Scientific Advice meeting with the MHRA in order to prepare an Investigational Medicinal Dossier for PRP, which will contribute to the preparation of a Clinical Trial Application (CTA) for a First-In-Human study in advanced cancer patients with solid tumors.
Scale up GMP manufacture of PRP for human studies.
Undertake detailed analysis of the two proenzymes (trypsinogen and chymotrypsinogen) and their activated enzyme forms (trypsin and chymotrypsin) from the PRP formulation by Liquid Chromatography-Mass Spectrometry. It is believed analysis of these four analytes will provide a better understanding of the bio-distribution of PRP in human blood plasma (pharmacokinetics). The intention is to develop and validate an analytical method to measure the pharmacokinetics of PRP that will provide important information for future Phase II clinical studies in pancreatic and ovarian cancer patients.
Currently progressing towards a First-In-Human study, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharma-Provides-Shareholder-Update-and-Goals-for-2018?id=183058
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPBC
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPBC
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPBC
$PPCB 038 JUST BECAUSE 99.999% OF THE WORLD NEVER HEARD OF IT, SHOULDN'T MEAN U SHOULDN'T. bouncing off 52week low of .031. 52 week high is 90 cents!
JUST BECAUSE 99.9999% OF TRADERS IN THE WHOLE WORLD haven't heard of this AUSTRALIAN CANCER BIOTECH gem doesn't mean you shouldn't. We all know that pharmaceutical stocks are the ones with the MOST POTENTIAL TO MAKE. Percentage RUNS IN THE TENS OF THOUSANDS across all markets, OTC TO NASDAQ. Now imagine the rum LOWFLIAT BIOTECHS MAKE. They are zipcode\life changers.
If you know me, you should already know. Snooze and lose. GRANTED CANCER PATENT FROM THE EU!?????
$PPCB this unknown battered\ bloodied #BIOTECH crushed down from 52 WEEK HIGH of 90 CENTS.
I'm not here to sell you a dream but this can break 10 cents in DAYS with volume. The float is that thin.
LETS TALK MATH HERE. LIKE stuff you can actually quantify and measure.
PPCB only has 38 million shares outstanding juxtaposed with over 10,0000 stocks in the OTC and it's in the .0001 percententile juxtaposed with other biotech stocks and there is no comparison its in the .000000000001 percentile. #FACT. Don't sleep?????
$PPCB Propanc Biopharma Provides Shareholder Update and Goals for 2018
PR Newswire
MELBOURNE, Australia, Feb. 12, 2018
MELBOURNE, Australia, Feb. 12, 2018 /PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced an update on the progress of the Company and its R&D activities in 2017 and its forecast for this year, as the Company looks towards commencing a First-In-Human (FIH) study for its lead product candidate, PRP, a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
Since the beginning of 2017, the Company has initiated and completed a number of activities, including:
Filed two Patent Cooperation Treaty (PCT) applications for a cancer treatment and composition of proenzymes for cancer treatment, respectively. The PCT application for a cancer treatment claims priority from two earlier Spanish patent applications filed in 2016. The PCT assists applicants in simultaneously seeking protection for an invention in over 150 countries.
Acceptance of a lead patent application for PRP from the Chinese Patent Office was received.
A GLP-Compliant toxicity study over a 28-day period was successfully completed, where no treatment related findings were observed. This concluded the preclinical development phase of PRP and provides a safety margin for a dosage of PRP to be administered in a First-In-Human study.
A method for detection of IR dye labelled trypsinogen and chymotrypsinogen in rat plasma was successfully validated. The assay was deemed to have acceptable precision and accuracy. It was also selective for the two IR dye labelled proenzymes, as opposed to the unlabelled proenzymes.
The U.S. Food and Drug Administration (the "FDA") granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.
A manufacturing process capable of purifying and stabilizing two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen were developed successfully.
A sandwich ELISA was developed for the determination of a mixture of chymotrypsinogen and trypsinogen in dose formulations and human serum. Further development work is necessary to validate the method for the analysis of the two proenzymes in human serum.
As a result of the activities completed in 2017, the Company intends to undertake the following activities:
Conduct a Scientific Advice meeting with the MHRA in order to prepare an Investigational Medicinal Dossier for PRP, which will contribute to the preparation of a Clinical Trial Application (CTA) for a First-In-Human study in advanced cancer patients with solid tumors.
Scale up GMP manufacture of PRP for human studies.
Undertake detailed analysis of the two proenzymes (trypsinogen and chymotrypsinogen) and their activated enzyme forms (trypsin and chymotrypsin) from the PRP formulation by Liquid Chromatography-Mass Spectrometry. It is believed analysis of these four analytes will provide a better understanding of the bio-distribution of PRP in human blood plasma (pharmacokinetics). The intention is to develop and validate an analytical method to measure the pharmacokinetics of PRP that will provide important information for future Phase II clinical studies in pancreatic and ovarian cancer patients.
Currently progressing towards a First-In-Human study, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharma-Provides-Shareholder-Update-and-Goals-for-2018?id=183058
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPBC
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPBC
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPBC
$PPBC .035 NOTHING WILL STOP THIS BIOTECH TRAIN!! Its not my problem if you never heard of it. JUST GRANTED AN EU PATENT. ONLY 38 MILLION O\S at 035???!!! #BIOTECH??!!
52 WEEK HIGH 90 CENTS. Based in Australia reason its unknown to American traders. Grab your TELESCOPE I'll save to you.
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials
Purification Process Achieves Pure and Stable Active Drug Substances, Engineering Runs to Commence
PR Newswire
MELBOURNE, Australia, Dec. 4, 2017
MELBOURNE, Australia, Dec. 4, 2017/PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has made significant recent progress towards full scale Good Manufacturing Process (GMP) manufacture of its lead product, PRP, for First-In-Human studies, expected to commence in 2018. Research and development activities conducted with its European Contract Manufacturing Organization (CMO) experienced in the production of biopharmaceuticals, have been successful in developing a process capable of purifying and stabilizing the two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen, which is an important requirement during the manufacturing process. As a result, the Company is set to commence engineering runs of manufacturing the finished drug product, prior to full scale GMP manufacture of PRP for human trials. PRP is a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
"We are delighted with the excellent progress made with our CMO in progressing PRP to its current stage of development and we are excited about our plans to move into First-In-Human studies next year," said Dr Julian Kenyon, Propanc Biopharma's Chief Scientific Officer. "Purifying and stabilizing each active drug substance of PRP has been technically challenging. This is due to the nature of the proenzymes which are able to auto-activate themselves, which is not unexpected for biological molecules of this nature. The work conducted by our research and development team to meet this challenge has been first class and we look forward to progressing PRP through to clinical development."
The Company expects to file its first Clinical Trial Application (CTA) for a First-In-Human study in the UK next year, initially treating late stage cancer patients with solid tumors, before progressing into two larger Phase II Proof of Concept studies in both pancreatic and ovarian cancer patients. Preclinical animal studies demonstrating proof of concept, in vivo, as well as the completion of a GLP-compliant, 28-day repeat-dose toxicology study, which helps to confirm the starting dose in humans by identifying the No Observable Adverse Effect Level (NOAEL) in an animal species, has the management team confident it has undertaken the steps necessary to achieve the best possible results in its planned human studies. This is further supported by the FDA granting Orphan Drug Designation of PRP for the treatment of one of its lead indications, pancreatic cancer, with a second application filed for ovarian cancer under evaluation.
"I am pleased with the progress of PRP and look forward to preparing our lead product for First-In-Human studies next year," said Professor Klaus Kutz, Propanc Biopharma's Chief Medical Officer. "The Company has undertaken significant work to prepare for this important milestone, and believe the product can benefit patients suffering from aggressive solid tumors, which are most often incurable. Extending life meaningfully, but without compromising the quality of life for patients, without the side effects normally associated with standard treatment regimens, remains a high priority. We remain hopeful that PRP can become a breakthrough product for many patients worldwide."
Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPBC .035 NOTHING WILL STOP THIS BIOTECH TRAIN!! Its not my problem if you never heard of it. JUST GRANTED AN EU PATENT. ONLY 38 MILLION O\S at 035???!!! #BIOTECH??!!
52 WEEK HIGH 90 CENTS. Based in Australia reason its unknown to American traders. Grab your TELESCOPE I'll save to you.
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials
Purification Process Achieves Pure and Stable Active Drug Substances, Engineering Runs to Commence
PR Newswire
MELBOURNE, Australia, Dec. 4, 2017
MELBOURNE, Australia, Dec. 4, 2017/PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has made significant recent progress towards full scale Good Manufacturing Process (GMP) manufacture of its lead product, PRP, for First-In-Human studies, expected to commence in 2018. Research and development activities conducted with its European Contract Manufacturing Organization (CMO) experienced in the production of biopharmaceuticals, have been successful in developing a process capable of purifying and stabilizing the two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen, which is an important requirement during the manufacturing process. As a result, the Company is set to commence engineering runs of manufacturing the finished drug product, prior to full scale GMP manufacture of PRP for human trials. PRP is a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
?
"We are delighted with the excellent progress made with our CMO in progressing PRP to its current stage of development and we are excited about our plans to move into First-In-Human studies next year," said Dr Julian Kenyon, Propanc Biopharma's Chief Scientific Officer. "Purifying and stabilizing each active drug substance of PRP has been technically challenging. This is due to the nature of the proenzymes which are able to auto-activate themselves, which is not unexpected for biological molecules of this nature. The work conducted by our research and development team to meet this challenge has been first class and we look forward to progressing PRP through to clinical development."
The Company expects to file its first Clinical Trial Application (CTA) for a First-In-Human study in the UK next year, initially treating late stage cancer patients with solid tumors, before progressing into two larger Phase II Proof of Concept studies in both pancreatic and ovarian cancer patients. Preclinical animal studies demonstrating proof of concept, in vivo, as well as the completion of a GLP-compliant, 28-day repeat-dose toxicology study, which helps to confirm the starting dose in humans by identifying the No Observable Adverse Effect Level (NOAEL) in an animal species, has the management team confident it has undertaken the steps necessary to achieve the best possible results in its planned human studies. This is further supported by the FDA granting Orphan Drug Designation of PRP for the treatment of one of its lead indications, pancreatic cancer, with a second application filed for ovarian cancer under evaluation.
"I am pleased with the progress of PRP and look forward to preparing our lead product for First-In-Human studies next year," said Professor Klaus Kutz, Propanc Biopharma's Chief Medical Officer. "The Company has undertaken significant work to prepare for this important milestone, and believe the product can benefit patients suffering from aggressive solid tumors, which are most often incurable. Extending life meaningfully, but without compromising the quality of life for patients, without the side effects normally associated with standard treatment regimens, remains a high priority. We remain hopeful that PRP can become a breakthrough product for many patients worldwide."
Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
$PPBC UNKNOWN BUT NOT FOR LONG. Lets get to 15 cents... FOR STARTERS
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials
Purification Process Achieves Pure and Stable Active Drug Substances, Engineering Runs to Commence
PR Newswire
MELBOURNE, Australia, Dec. 4, 2017
MELBOURNE, Australia, Dec. 4, 2017 /PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has made significant recent progress towards full scale Good Manufacturing Process (GMP) manufacture of its lead product, PRP, for First-In-Human studies, expected to commence in 2018. Research and development activities conducted with its European Contract Manufacturing Organization (CMO) experienced in the production of biopharmaceuticals, have been successful in developing a process capable of purifying and stabilizing the two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen, which is an important requirement during the manufacturing process. As a result, the Company is set to commence engineering runs of manufacturing the finished drug product, prior to full scale GMP manufacture of PRP for human trials. PRP is a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
"We are delighted with the excellent progress made with our CMO in progressing PRP to its current stage of development and we are excited about our plans to move into First-In-Human studies next year," said Dr Julian Kenyon, Propanc Biopharma's Chief Scientific Officer. "Purifying and stabilizing each active drug substance of PRP has been technically challenging. This is due to the nature of the proenzymes which are able to auto-activate themselves, which is not unexpected for biological molecules of this nature. The work conducted by our research and development team to meet this challenge has been first class and we look forward to progressing PRP through to clinical development."
The Company expects to file its first Clinical Trial Application (CTA) for a First-In-Human study in the UK next year, initially treating late stage cancer patients with solid tumors, before progressing into two larger Phase II Proof of Concept studies in both pancreatic and ovarian cancer patients. Preclinical animal studies demonstrating proof of concept, in vivo, as well as the completion of a GLP-compliant, 28-day repeat-dose toxicology study, which helps to confirm the starting dose in humans by identifying the No Observable Adverse Effect Level (NOAEL) in an animal species, has the management team confident it has undertaken the steps necessary to achieve the best possible results in its planned human studies. This is further supported by the FDA granting Orphan Drug Designation of PRP for the treatment of one of its lead indications, pancreatic cancer, with a second application filed for ovarian cancer under evaluation.
"I am pleased with the progress of PRP and look forward to preparing our lead product for First-In-Human studies next year," said Professor Klaus Kutz, Propanc Biopharma's Chief Medical Officer. "The Company has undertaken significant work to prepare for this important milestone, and believe the product can benefit patients suffering from aggressive solid tumors, which are most often incurable. Extending life meaningfully, but without compromising the quality of life for patients, without the side effects normally associated with standard treatment regimens, remains a high priority. We remain hopeful that PRP can become a breakthrough product for many patients worldwide."
Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPBC pump??? No need to pump a gem LMFAOOOOOOO. See u at 15 cents
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB
PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB PPCB